Loretta Nastoupil, MD
Hematology & Oncology · Houston, TXNPI 1407048630
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $229,626 of the $308,718 with a category attached, or 74.4%. 27 manufacturers reported payments, led by Gilead at 26.8% of the total. Reporting peaked in 2019 at $93,468 and has fallen 81.7% since, to $17,112 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $1201.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$83K
- Bristol Myers Squibb$58K
- E.r. Squibb & Sons, L.L.C.$21K
- Janssen Global Services, LLC$20K
- F. Hoffmann-la Roche AG$18K
- Genentech, Inc.$17K
- plus $92K from 21 others
Across 222 payments — averaging $81,749 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$7.8M
- Bristol Myers Squibb$2.7M
- Genentech, Inc.$2.6M
- Gilead$2.5M
- Merck$1.1M
- Janssen Research & Development, LLC$325K
- plus $1.1M from 9 others
What the payments were for
- Consulting fees$229,62674%
- Speaking & faculty fees$51,00817%
- Travel & lodging$20,2877%
- Food & beverage$6,4712%
- Education$1,3250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 66 | $82,706 |
| Bristol Myers Squibb | 48 | $58,438 |
| E.r. Squibb & Sons, L.L.C. | 13 | $21,178 |
| Janssen Global Services, LLC | 8 | $20,220 |
| F. Hoffmann-la Roche AG | 20 | $17,882 |
| Genentech, Inc. | 22 | $16,692 |
| Novartis | 11 | $11,785 |
| Bayer | 3 | $10,780 |
| AstraZeneca | 5 | $8,939 |
| Genentech USA, Inc. | 11 | $8,903 |
| Pfizer | 1 | $8,820 |
| Epizyme, Inc. | 2 | $6,525 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $5,775 |
| AbbVie | 6 | $5,441 |
| Incyte Corporation | 3 | $4,613 |
| Genmab U.S., Inc. | 7 | $3,346 |
| Regeneron | 4 | $3,112 |
| ADC Therapeutics America, Inc. | 4 | $2,695 |
| Morphosys, US Inc. | 1 | $2,655 |
| Beigene USA, Inc. | 2 | $2,625 |
| Merck | 5 | $1,931 |
| Eisai CO., LTD. | 1 | $1,691 |
| Daiichi Sankyo Inc. | 4 | $825 |
| Astrazeneca UK Limited | 2 | $745 |
| Seagen Inc. | 3 | $170 |
| TG Therapeutics, Inc. | 2 | $169 |
| Janssen Scientific Affairs, LLC | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$308,718 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 38 | $563,688 |
| BrukinsaZanubrutinib | 24 | $303,963 |
| EliquisApixaban | 17 | $12,071 |
| ValacyclovirValacyclovir Hcl | 36 | $1,267 |
| Dexamethasone | 38 | $446 |
| Anastrozole | 16 | $397 |
| Prochlorperazine Maleate | 32 | $377 |
| Oxycodone Hcl | 14 | $235 |
| Ondansetron Hcl | 36 | $199 |
| Prednisone | 35 | $145 |
| Levothyroxine Sodium | 13 | $118 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $8,939 | $563,68838 claims |
| Beigene USA, Inc.Brukinsa | $2,625 | $303,96324 claims |
| PfizerEliquis | $8,820 | $12,07117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
- Luhua WangHouston$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.